

BIOGEN INC.
Form 4
March 02, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
COVINO GREGORY F

(Last) (First) (Middle)

BIOGEN INC., 225 BINNEY
STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
BIOGEN INC. [BIIB]

3. Date of Earliest Transaction
(Month/Day/Year)
02/28/2017

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title ____ Other (specify
below) below)

VP, Chief Accounting Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	02/28/2017 ⁽¹⁾		M		76	A	\$ 0	3,988.8231	D
Common Stock	02/28/2017 ⁽¹⁾		F		25	D	\$ 284.75	3,963.8231	D
Common Stock	02/28/2017 ⁽²⁾		M		163	A	\$ 0	4,126.8231	D
Common Stock	02/28/2017 ⁽²⁾		F		53	D	\$ 287.63	4,073.8231	D
Common Stock	02/28/2017 ⁽³⁾		M		321	A	\$ 0	4,394.8231	D

Edgar Filing: BIOGEN INC. - Form 4

Common Stock	02/28/2017 ⁽³⁾	F	8	D	\$ 274.76	4,386.8231	D
Common Stock	02/28/2017 ⁽³⁾	M	121	A	\$ 0	4,507.8231	D
Common Stock	02/28/2017 ⁽³⁾	F	3	D	\$ 274.76	4,504.8231	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Fair Value of Derivative Security (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	\$ 0	02/28/2017		J	143 <u>(4)</u>	<u>(5)</u>	02/12/2017	Common Stock	143
Restricted Stock Unit	\$ 0	02/28/2017		J	131 <u>(4)</u>	<u>(6)</u>	02/22/2019	Common Stock	131
Restricted Stock Unit	\$ 0	02/28/2017		J	128 <u>(4)</u>	<u>(5)</u>	02/23/2018	Common Stock	128
Restricted Stock Unit	\$ 0	02/28/2017 <u>(1)</u>		M	76 <u>(7)</u>	<u>(5)</u>	02/23/2018	Common Stock	76 <u>(7)</u>
Restricted Stock Unit	\$ 0	02/28/2017 <u>(2)</u>		M	163 <u>(8)</u>	<u>(6)</u>	02/22/2019	Common Stock	163 <u>(8)</u>
Restricted Stock Unit	\$ 0	02/28/2017 <u>(3)</u>		M	321 <u>(9)</u>	<u>(10)</u>	02/12/2017	Common Stock	321 <u>(9)</u>
Restricted Stock Unit	\$ 0	02/28/2017 <u>(3)</u>		M	121 <u>(11)</u>	<u>(5)</u>	02/12/2017	Common Stock	121 <u>(11)</u>

Edgar Filing: BIOGEN INC. - Form 4

- (11) This award was previously reported as covering 258 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.